Full Description
This fully-updated third edition of Scleroderma: From Pathogenesis to Comprehensive Managementbuilds upon the well-regarded approach in the previous editions to provide integrated, concise, and up-to-date synthesis of current concepts of pathogenesis and modern approaches to management of systemic sclerosis (scleroderma). With a multidisciplinary approach to comprehensive care, this book is easily accessible for health care professionals in many fields. Comprised of the authoritative work of international experts, the new edition includes extensive updated material reflecting major developments in the field. It presents a succinct and thoughtful synthesis of current pathomechanistic concepts, providing a valuable reference tool for basic and translational investigators working in the field. Scleroderma: From Pathogenesis to Comprehensive Management serves as an essential, all-inclusive and fully up to date resource for rheumatologists, pulmonologists, cardiologists, gastroenterologists, nephrologists and all those involved in the care of scleroderma patients.
Contents
Preface.- . Foreword.- Section 1: Introduction. .- 1. Historical perspective of scleroderma.- Section 2: Epidemiology, Genetics and Classification. .- 2. Epidemiology, Environmental and Infectious Risk Factors.- 3. Influence of ethnicity and sex bias in systemic sclerosis.- 4. Genetic Factors.- 5. Classification and Disease Subsets in Clinical Practice.- 6. Clustering and evolving concepts for subclassification.- 7. The Clinical Aspects of Autoantibodies.- 8. Systemic sclerosis overlap syndromes.- 9. Juvenile Localized and Systemic Scleroderma.- 10. Morphea (Localized scleroderma).- Section 3: The Biological Basis of Systemic Sclerosis. .- 11. Scleroderma Mimics.- 12. Introduction: The Etiopathogenesis of Systemic Sclerosis - an Integrated Overview.- 13. Pathology of Systemic Sclerosis.- 14. Inflammation And Immunity In Systemic Sclerosis.- 15. Autoantibodies as Markers and Possible Mediators of Scleroderma Pathogenesis.- 16. Mechanisms of Vascular Disease.- 17. Biomarkers in Systemic Sclerosis.- 18. Cellular and molecular mechanisms of fibrosis in systemic sclerosis.- 19. Overview of Animal Models.- Section 4: Cardiovascular Manifestations and Management. .- 20. Overview of management and outcome assessment in systemic sclerosis.- 21. Raynaud's Phenomenon, Digital Ulcers and Nailfold Capillaroscopy.- 22. Renal crisis and other renal manifestations.- 23. Cardiac Involvement: Evaluation And Management.- Section 5: Pulmonary Manifestations and Management. .- 24. Overview of lung involvement.- 25. Clinical assessment of ILD.- 26. Lung Imaging Perspective in Scleroderma.- 27. Treatment of Interstitial Lung Disease in systemic sclerosis.- 28. Pathogenesis of Pulmonary Arterial Hypertension.- 29. Clinical Assessment of Pulmonary Hypertension.- 30. The management of pulmonary arterial hypertension in the setting of systemic sclerosis.- Section 6: Gastrointestinal Manifestations and Management. .- 31. Overview of gastrointestinal tract involvement.- 32. UpperGastrointestinal Tract: Manifestations of Systemic Sclerosis.- 33. Lower Gastrointestinal Tract Involvement: Understanding the Interplay of Motility, the Microbiome and Nutrition.- Section 7: Skin, Musculoskeletal and Other Complications. .- 34. Evaluation and Management of Skin Disease.- 35. Calcinosis.- 36. Tendons, Joints, and Bone.- 37. Skeletal Muscle Involvement.- 38. Cancer in Systemic Sclerosis.- 39. Overlooked Manifestations.- 40. Pregnancy.- 41. Vaccinations in Patients with Systemic Sclerosis.- Section 8: Management and Outcome Assessment.- 42. Management Of Progressive Skin Involvement In Diffuse Scleroderma.- 43. Hematopoietic stem cell transplantation.- 44. Immune targeted therapies in SSc..- 45. Physical and Occupational Therapy.- 46. Psychosocial Issues and Care for Patients with Systemic Sclerosis.- Section 9: Case Studies: Approach to Complex Clinical Problems. .- 47. Measuring Disease Activity and Outcomes in Clinical Trials.- 48. Evolving clinical trial design andinnovative approaches.- 49. Drug Development and Regulatory Considerations for Systemic Sclerosis Therapies.- 50. Managing the Ischemic Finger in Scleroderma.- 51. Scleroderma Renal Crisis: a case study.- 52. Rapid diffuse skin disease with progressive joint contractures.- 53. Management of the Scleroderma Patient with Pulmonary Arterial Hypertension Failing Initial Therapy.- 54. Pseudo-obstruction with malabsorption and malnutrition.- 55. Progressive Interstitial Lung Disease Non-Responsive to Immunosuppressive Therapy.- 56. Body Image Distress in Scleroderma.- 57. Managing Complicated Digital Ulcers.- 58. Lower Limb Ulceration.
